Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 12/2007

01.12.2007 | Symposium of the Aging Ovary

Too old for IVF: are we discriminating against older women?

verfasst von: Norbert Gleicher, Andrea Weghofer, David Barad

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

In vitro fertilization (IVF) in women of advanced age (>42 years) represents only 5%, a comparatively minute part, of the national IVF experience in the United States (US). In view of evolving population dynamics, it, however, also represents proportionally a rather quickly expanding patient need. Because of access restrictions at many IVF programs, this market does not live up to its potential. As best demonstrated by the 2004 US National Summary and Fertility Clinic Report, which for the first time reported pregnancies and births above age 45 year, IVF in women of advanced reproductive age represents a cutting edge area of interest for improving current IVF outcomes. Access to IVF should, therefore, not be withheld based on female age and/or baseline FSH levels. Instead, a definition of acceptable minimal pregnancy and life birth rates could be used to define the limits of offered access to IVF, independent of age and/or baseline FSH levels.
Literatur
1.
Zurück zum Zitat Wright VC, Chang J, Jeng G, Chen M, Macaluso M. Assisted reproductive technology surveillance—United States, 2004. MMWR Surveill Summ 2007;56(6):1–22.PubMed Wright VC, Chang J, Jeng G, Chen M, Macaluso M. Assisted reproductive technology surveillance—United States, 2004. MMWR Surveill Summ 2007;56(6):1–22.PubMed
2.
Zurück zum Zitat Hamilton BE, Martin JA, Sutton PD. Births: preliminary data for 2003. Natl Vital Stat Rep 2004;53(9):1–17.PubMed Hamilton BE, Martin JA, Sutton PD. Births: preliminary data for 2003. Natl Vital Stat Rep 2004;53(9):1–17.PubMed
3.
Zurück zum Zitat Hamilton BE, Martin JA, Sutton PD. Births: preliminary data for 2002. Natl Vital Stat Rep 2003;51(11):1–20. Hamilton BE, Martin JA, Sutton PD. Births: preliminary data for 2002. Natl Vital Stat Rep 2003;51(11):1–20.
4.
Zurück zum Zitat Gleicher N, Barad D. Unexplained infertility: does it really exist? Hum Reprod 2006;21(8):1951–5.PubMedCrossRef Gleicher N, Barad D. Unexplained infertility: does it really exist? Hum Reprod 2006;21(8):1951–5.PubMedCrossRef
5.
Zurück zum Zitat Assisted Reproductive Technology Success rates. National Summary and Fertility Clinic Reports. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention December 2006. Assisted Reproductive Technology Success rates. National Summary and Fertility Clinic Reports. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention December 2006.
6.
Zurück zum Zitat Faddy MJ. Follicle dynamics during ovarian ageing. Mol Cell Endocrinol 2000;163(1–2):43–8.PubMedCrossRef Faddy MJ. Follicle dynamics during ovarian ageing. Mol Cell Endocrinol 2000;163(1–2):43–8.PubMedCrossRef
7.
Zurück zum Zitat Faddy MJ, Gosden RG. A mathematical model of follicle dynamics in the human ovary. Hum Reprod 1995;10(4):770–5.PubMed Faddy MJ, Gosden RG. A mathematical model of follicle dynamics in the human ovary. Hum Reprod 1995;10(4):770–5.PubMed
8.
Zurück zum Zitat ASRM. Aging and infertility in women: a committee opinion. Fertil Steril 2002;78(1):215–9.CrossRef ASRM. Aging and infertility in women: a committee opinion. Fertil Steril 2002;78(1):215–9.CrossRef
9.
Zurück zum Zitat Scott RT Jr. Diminished ovarian reserve and access to care. Fertil Steril 2004;81(6):1489–92. discussion 496–7.PubMedCrossRef Scott RT Jr. Diminished ovarian reserve and access to care. Fertil Steril 2004;81(6):1489–92. discussion 496–7.PubMedCrossRef
10.
Zurück zum Zitat Barad DH, Weghofer A, Gleicher N. Age-specific levels for basal follicle-stimulating hormone assessment of ovarian function. Obstet Gynecol 2007;109(6):1404–10.PubMed Barad DH, Weghofer A, Gleicher N. Age-specific levels for basal follicle-stimulating hormone assessment of ovarian function. Obstet Gynecol 2007;109(6):1404–10.PubMed
11.
Zurück zum Zitat Frattarelli JL, Levi AJ, Miller BT, Segars JH. A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles. Fertil Steril 2003;80(2):350–5.PubMedCrossRef Frattarelli JL, Levi AJ, Miller BT, Segars JH. A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles. Fertil Steril 2003;80(2):350–5.PubMedCrossRef
12.
Zurück zum Zitat van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17(12):3065–71.PubMedCrossRef van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17(12):3065–71.PubMedCrossRef
13.
Zurück zum Zitat Chuang CC, Chen CD, Chao KH, Chen SU, Ho HN, Yang YS. Age is a better predictor of pregnancy potential than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization. Fertil Steril 2003;79(1):63–8.PubMedCrossRef Chuang CC, Chen CD, Chao KH, Chen SU, Ho HN, Yang YS. Age is a better predictor of pregnancy potential than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization. Fertil Steril 2003;79(1):63–8.PubMedCrossRef
14.
Zurück zum Zitat van Rooij IA, Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization. Fertil Steril 2003;79(3):482–8.PubMedCrossRef van Rooij IA, Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization. Fertil Steril 2003;79(3):482–8.PubMedCrossRef
15.
Zurück zum Zitat van Rooij IA, de Jong E, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment. Fertil Steril 2004;81(6):1478–85.PubMedCrossRef van Rooij IA, de Jong E, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment. Fertil Steril 2004;81(6):1478–85.PubMedCrossRef
16.
Zurück zum Zitat Wolff EF, Taylor HS. Value of the day 3 follicle-stimulating hormone measurement. Fertil Steril 2004;81(6):1486–8. discussion 496–7.PubMedCrossRef Wolff EF, Taylor HS. Value of the day 3 follicle-stimulating hormone measurement. Fertil Steril 2004;81(6):1486–8. discussion 496–7.PubMedCrossRef
17.
Zurück zum Zitat Toner JP. Modest follicle-stimulating hormone elevations in younger women: warn but don't disqualify. Fertil Steril 2004;81(6):1493–5. discussion 496–7.PubMedCrossRef Toner JP. Modest follicle-stimulating hormone elevations in younger women: warn but don't disqualify. Fertil Steril 2004;81(6):1493–5. discussion 496–7.PubMedCrossRef
18.
Zurück zum Zitat Spandorfer SD, Bendikson K, Dragisic K, Schattman G, Davis OK, Rosenwaks Z. Outcome of in vitro fertilization in women 45 years and older who use autologous oocytes. Fertil Steril 2007;87(1):74–6.PubMedCrossRef Spandorfer SD, Bendikson K, Dragisic K, Schattman G, Davis OK, Rosenwaks Z. Outcome of in vitro fertilization in women 45 years and older who use autologous oocytes. Fertil Steril 2007;87(1):74–6.PubMedCrossRef
19.
Zurück zum Zitat Nikolaou D, Templeton A. Early ovarian ageing: a hypothesis. Detection and clinical relevance. Hum Reprod 2003;18(6):1137–9.PubMedCrossRef Nikolaou D, Templeton A. Early ovarian ageing: a hypothesis. Detection and clinical relevance. Hum Reprod 2003;18(6):1137–9.PubMedCrossRef
20.
Zurück zum Zitat Gleicher N, Barad D. “Ovarian age-based” stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization. Fertil Steril 2006;86(6):1621–5.PubMedCrossRef Gleicher N, Barad D. “Ovarian age-based” stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization. Fertil Steril 2006;86(6):1621–5.PubMedCrossRef
21.
Zurück zum Zitat Weghofer A, Barad D, Li J, Gleicher N. Aneuploidy rates in embryos from women with prematurely declining ovarian function: a pilot study. Fertil Steril 2007;88(1):90–4.PubMedCrossRef Weghofer A, Barad D, Li J, Gleicher N. Aneuploidy rates in embryos from women with prematurely declining ovarian function: a pilot study. Fertil Steril 2007;88(1):90–4.PubMedCrossRef
22.
Zurück zum Zitat Hull MG, Fleming CF, Hughes AO, McDermott A. The age-related decline in female fecundity: a quantitative controlled study of implanting capacity and survival of individual embryos after in vitro fertilization. Fertil Steril 1996;65(4):783–90.PubMed Hull MG, Fleming CF, Hughes AO, McDermott A. The age-related decline in female fecundity: a quantitative controlled study of implanting capacity and survival of individual embryos after in vitro fertilization. Fertil Steril 1996;65(4):783–90.PubMed
23.
Zurück zum Zitat Marcus SF, Brinsden PR. In-vitro fertilization and embryo transfer in women aged 40 years and over. Hum Reprod Update 1996;2(6):459–68.PubMedCrossRef Marcus SF, Brinsden PR. In-vitro fertilization and embryo transfer in women aged 40 years and over. Hum Reprod Update 1996;2(6):459–68.PubMedCrossRef
24.
Zurück zum Zitat Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006;21(11):2845–9.PubMedCrossRef Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006;21(11):2845–9.PubMedCrossRef
25.
Zurück zum Zitat Brill H, Barad DH, Gleicher N. O-289: Dehydroepiandrosterone (DHEA) supplementation and pregnancy outcome: effect on pregnancy rate and speed of conception. Fertil Steril 2006;86(3, Supplement 1):S124–S5.CrossRef Brill H, Barad DH, Gleicher N. O-289: Dehydroepiandrosterone (DHEA) supplementation and pregnancy outcome: effect on pregnancy rate and speed of conception. Fertil Steril 2006;86(3, Supplement 1):S124–S5.CrossRef
26.
Zurück zum Zitat Thornton K, Ryley D, Alper M, Ezcurra D. 2):S141. S. IVF outcome in women over age 40 years with elevated cycle day 3 FSH (≥10 mIU/mL). Fertil Steril 2006;86(Suppl 2):S141. Thornton K, Ryley D, Alper M, Ezcurra D. 2):S141. S. IVF outcome in women over age 40 years with elevated cycle day 3 FSH (≥10 mIU/mL). Fertil Steril 2006;86(Suppl 2):S141.
27.
Zurück zum Zitat Hernandez J, Sanabria V, Chinea E, Palumbo A. Reproductive outcome in women 40 and older undergoing in vitro fertilization (IVF). Fertil Steril 2006;86(Suppl 2):S166–7.CrossRef Hernandez J, Sanabria V, Chinea E, Palumbo A. Reproductive outcome in women 40 and older undergoing in vitro fertilization (IVF). Fertil Steril 2006;86(Suppl 2):S166–7.CrossRef
28.
Zurück zum Zitat Watt AH, Legedza AT, Ginsburg ES, Barbieri RL, Clarke RN, Hornstein MD. The prognostic value of age and follicle-stimulating hormone levels in women over forty years of age undergoing in vitro fertilization. J Assist Reprod Genet 2000;17(5):264–8.PubMedCrossRef Watt AH, Legedza AT, Ginsburg ES, Barbieri RL, Clarke RN, Hornstein MD. The prognostic value of age and follicle-stimulating hormone levels in women over forty years of age undergoing in vitro fertilization. J Assist Reprod Genet 2000;17(5):264–8.PubMedCrossRef
29.
Zurück zum Zitat Osmanagaoglu K, Tournaye H, Kolibianakis E, Camus M, Van Steirteghem A, Devroey P. Cumulative delivery rates after ICSI in women aged >37 years. Hum Reprod 2002;17(4):940–4.PubMedCrossRef Osmanagaoglu K, Tournaye H, Kolibianakis E, Camus M, Van Steirteghem A, Devroey P. Cumulative delivery rates after ICSI in women aged >37 years. Hum Reprod 2002;17(4):940–4.PubMedCrossRef
30.
Zurück zum Zitat Awonuga A, Merhi Z, Grazi R. Intrauterine inseminations versus in vitro fertilization in infertile women 40 years and older. Fertil Steril 2006;86(Suppl 2):S143.CrossRef Awonuga A, Merhi Z, Grazi R. Intrauterine inseminations versus in vitro fertilization in infertile women 40 years and older. Fertil Steril 2006;86(Suppl 2):S143.CrossRef
31.
Zurück zum Zitat Gleicher N, Barad D. The relative myth of elective single embryo transfer. Hum Reprod 2006;21(6):1337–44.PubMedCrossRef Gleicher N, Barad D. The relative myth of elective single embryo transfer. Hum Reprod 2006;21(6):1337–44.PubMedCrossRef
Metadaten
Titel
Too old for IVF: are we discriminating against older women?
verfasst von
Norbert Gleicher
Andrea Weghofer
David Barad
Publikationsdatum
01.12.2007
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 12/2007
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-007-9182-1

Weitere Artikel der Ausgabe 12/2007

Journal of Assisted Reproduction and Genetics 12/2007 Zur Ausgabe

Symposium of the Aging Ovary

Editorial

JARG Blog

JARG blog

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.